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Abstract
Purpose of Review This review aims to make the oral health practitioner and researcher aware of autoimmune diseases that
present in the mouth and have implications for oral health. Specifically, the autoimmune pathophysiology, examples of treat-
ments, sequelae, and impact on oral health will be discussed. The limitations of our current knowledge and understanding of these
diseases will also be highlighted.
Recent Findings Over the past decade, it has become clear that there is a bidirectional relationship between oral health and
autoimmune disease at other body sites; including diabetes and rheumatoid arthritis. Improving the oral health of patients with
autoimmune diseases may reduce morbidity associated with such diseases.
Summary Autoimmune diseases impact the oral cavity both directly and indirectly and are increasing in prevalence. As such,
there is a growing need for the oral health practitioners to be aware of how autoimmune disease impacts the oral cavity. Further
research is necessary to improve our understanding of the bidirectional relationship between oral health and autoimmune disease.
Keywords Oral health . Oral disease . Autoimmune disease
Introduction
Autoimmune diseases (ADs) impact oral health, both directly
and indirectly [1••]. This review will discuss ADs that present
in the oral cavity as well as ADs affecting other body sites that
impact on oral health. It is important for dental and medical
practitioners to understand the relationships and challenges
ADs present to oral health, and the bidirectional impacts be-
tween AD and oral health.
ADs are defined by their aetiology; the targeting of self anti-
gens by the host immune system [2]. Auto-antigens are targeted
by self-reactive T cells or antibodies directed against self, termed
auto-antibodies [3]. The auto-antigens’ targets include host cells,
tissue, or commensal microbiota. Self-reactive lymphocytes are
ubiquitously generated; however, these are usually eliminated or
regulated before they can elicit their effects. There are multiple
mechanisms that regulate this process, collectively known as
tolerance. However, breach of tolerance occurs if this system
becomes dysregulated and this can result in autoimmune disease
[3, 4]. The dysregulation in autoimmunity is thought to be mul-
tifactorial, arising from genetic and environmental factors. ADs
can be initiated following infection and this has raised the theory
of molecular mimicry; the antigens expressed by an infective
pathogen resemble those of the host, resulting in cross-
reactivity and potentially autoimmune disease [5, 6] (Fig. 1).
ADs incidence has increased over the last decade and new
therapeutics both improve and prolong the life of patients with
such disease. This means that oral health professionals will
encounter more patients with these diseases [7, 8]. Having
the knowledge about ADs and their oral manifestations is
essential in delivering quality care to patients with these
debilitating diseases. In the following sections, specific ex-
amples of AD are discussed, with particular reference to
their relationship with the oral cavity.
Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterised by progressive joint destruction and pain and
swelling of joints. RA affects 1% of the UK population [9].
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The exact aetiology of the disease is not fully understood;
however, both genetic and environmental factors play a key
role in RA pathogenesis. One potential trigger of RA is mi-
crobial dysbiosis and its interaction with the human host, and
the periodontium is a site that has been implicated as a trigger
for RA [10] (Fig. 2A).
Auto-antibodies against citrullinated peptides (ACPAs) are
present in 50–70% of patients [11, 12] and are associated with
more severe disease. The auto-antibodies form immune com-
plexes leading to complement activation, perpetuating inflam-
mation and pathology. However, RA is heterogeneous; there
are patients, described as ‘sero-negative’, who do not present
with identifiable auto-antibodies [11, 13]. The extent to which
this broad spectrum of disease presentation represents differ-
ing disease aetiologies is unconfirmed.
Periodontal disease is more prevalent in patients with rheu-
matoid arthritis and 80–85% of patients with RA suffer from
periodontitis, compared with 40% of non-RA control patients
[14••]. Patients with RA also demonstrate more alveolar bone
loss compared to non-RA controls [15]. Specifically, it has
been suggested that Porphyromonas gingivalis, a key patho-
gen in the aetiology of periodontal disease (PD), plays a role in
the development of RA [16]. In a mouse model or RA, when
periodontal disease is concurrently induced with P. gingivalis,
there is an exacerbation of synovitis, compared to controls
[17•]. Intriguingly, patients with RA show an elevated anti-
body response to P. gingivalis virulence factors [18•].
Inflammatory mediators such as interleukin 1 beta (IL-1β)
and tumour necrosis factor alpha (TNF-α) have been shown to
be important in RA and PD pathogenesis [19, 20], and step
changes in understanding of RA pathogenesis have led to cyto-
kine and immune cell inhibition strategies for RA treatment.
There is a well-documented clinical benefit to anti-TNF-α treat-
ments for RA patients. Further to this research has shown that
patients with RA and PD receiving anti-TNF-α treatment have
diminished PD. Moreover, it has been suggested that some of
these cytokine targeting therapies may be less effective in pa-
tients who have uncontrolled PD. There is suggestion that anti-
TNF-α and potentially other anti-pro-inflammatory cytokine
therapeutics may be beneficial in the treatment of PD. [21]
Importantly RA is also associated with Sjögren’s
Syndrome (SjS), which is discussed later in this review. RA
mainly effects the joints of the hands and legs; however, tem-
poromandibular joints can also be affected [22]. The preva-
lence of temporomandibular joint dysfunction (TMD) is be-
tween 6 and 12% of the general population. A recent study of
TMD in RA patients have shown around 90% of patients with
RA have concurrent TMJ symptoms [23, 24]. Patients with
RA and TMD show more evidence of synovitis within the
TMJ when examined via MRI scanning [22].
Fig. 1 Model for the microbial induction of autoimmune disease via
molecular mimicry—a mechanism of autoimmunity proposed in
rheumatoid arthritis, diabetes mellitus, lichen planus, and pemphigoid
(A). Following microbial infection, potentially at a site distant to the
target of the autoimmune response, certain antigenic determinants of
bacteria and viruses are engulfed and processed by antigen presenting
cells (APCs) (B). Following processing, the peptide is presented by the
APCs to antigen-specific naïve T cells, via the major histocompatibility
complex II (MHC II), triggering T cell activation (C). Once activated, T
cells provide co-stimulatory signals to B cells, triggering activation and
production of antigen-specific antibodies (D). Whilst these antibodies
recognise and bind to bacterial antigens (E), they also recognise and
bind to self-peptides displayed on specific tissue sites (F). Molecular
mimicry of microbial antigens with self-peptides may potentially also
result in the activation of autoreactive T cells and cytokine production,
leading to inflammation and tissue damage. Image created with
BioRender
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Sjögren’s Syndrome
The cardinal sign of SjS is destruction of exocrine glands,
most notably salivary and lacrimal glands. Destruction of sal-
ivary glands causes decreased salivary flow; resulting in
xerostomia. This causes an increased risk of dental caries,
fungal infections, and chronic oral discomfort. As such, den-
tists play a key role in the diagnosis and management of this
disease [25].
SjS pathogenesis occurs through a combination of genetic,
environmental, and hormonal factors, leading to the develop-
ment of inflammation and autoimmune responses to the exo-
crine glands [26]. There are two variants of SjS; primary—
which occurs in isolation without other systemic autoimmune
diseases; and secondary which occurs following a diagnosis of
systemic autoimmune disease; most commonly RA.
Histologically, there is lymphocytic infiltration of the salivary
and lacrimal glands. The exact role of lymphocytes in the
pathogenesis of SjS is yet to be identified; however, defects
in immune tolerance are an important aspect of disease devel-
opment. The commonly cited auto-antibodies in SjS are
antigens against La/SSB/TRIM21 and Ro60/TROVE2. As
such, these act as important diagnostic markers for SjS [26].
There have been multiple classification criteria for SjS pre-
viously. The most recent are those developed by American
College of Rheumatology (ACR) and the European League
Against Rheumatism (EULAR) in 2016 [26]. This classifica-
tion allows for the simultaneous assessment of multiple sys-
tems that may be involved in SjS. As such, it has proven to be
effective at both reaching a diagnosis and monitoring disease
progression. It has also been beneficial in randomised con-
trolled trials; important due to the potential development of
biologics and other agents that may be used in the treatment of
SjS [27].
A recent systematic review showed that 60.82 (95% CI
43.69 to 77.94) per 100,000 people suffer from SjS, with a
strong female predilection ratio of 10.72(95% CI 7.35 to
15.62), the mean age of patients with SjS was 56.16(95% CI
52.54 to 59.78) [28, 29].
Currently, there is no cure for SjS, as such management is
centred around slowing disease development and symptomat-
ic relief. Despite biologic agents being routinely used for other
Fig. 2 The effects of autoimmune diseases in the oral cavity. In
rheumatoid arthritis, there is a predisposition to periodontitis, and
infection with periodontal disease associated bacteria has been proposed
to contribute to pathogenesis of rheumatoid arthritis (A). In lichen planus,
CD8+ T lymphocytes predominate in oral lesions, characterised by
inflammation, swelling, and damage to oral keratinocytes (B). In
pemphigus, intra-epithelial blisters form due to self-recognising
antibodies directed against desmosomes, which are crucial for cell-cell
attachment (C). Alternatively, in pemphigoid, antibodies become directed
against hemidesmosomes, which function to anchor epithelial cells to the
lamina propria. The result of this is the formation of large, fluid-filled
blisters between the cells and lamina propria, which in severe cases may
cause detachment (D). Detailed schematic of pemphigus i) (red antibody
against desmosomes and pemphigoid ii) (blue antibody against
hemidesmosomes (E). Image created using BioRender
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ADs, they are not in routine use in SjS; however, work con-
tinues in this area [30].
Management from the dental team focuses on prevention
and reducing oral discomfort. This includes regular oral ex-
amination, provision of high-fluoride toothpaste alongside
other caries preventative methods. Saliva replacements often
offer little benefit, as such conservative advice including
drinking water regularly and using chewing gum may provide
some relief for patients [31]. Patients with SjS are at an
increased risk of developing B cell lymphoma, which may
present as swelling local to the oral cavity and salivary
glands, reinforcing the need for regular dental assessment
and vigilance with regard to newly arising swellings [25].
Diabetes
Chronic hyperglycaemia of diabetes results in damage to the
cardiovascular system, kidneys, eyes, nerves, and patients are
often immunocompromised [32]. There are multiple oral im-
plications of diabetes. This review focuses on type 1 diabetes
due to its autoimmune pathophysiology [33]. Diabetes treat-
ment focuses on regulating blood glucose levels through reg-
ular testing of levels, the use of insulin, and diet control.
Type 1 diabetes arises from the autoimmune destruction of
insulin-secreting pancreatic β cells causing decreased insulin
production. Further to this long-standing disease often results
in a total loss of insulin production. However, 10–30% of
patients have no detectable auto-antibodies, and in these cases,
the pathogenesis of diabetes remains unclear [34••].
Diabetes has conclusively been shown to be a risk factor
for periodontal disease, and this relationship has been exten-
sively studied and reviewed [35, 36]. Elevated HbA1c is as-
sociated with greater prevalence of disease and periodontal
destruction, and glycaemic control appears to be the main
predictor of attachment loss and subsequent tooth loss.
Specifically, an HbA1c of greater than 7.0% appears to deter-
mine if a diabetic has and elevated PD risk [37•].
Periodontal disease negatively impacts glycaemic control
and the development of nephropathy in diabetic patients [38,
39]. A recent systematic review of HbA1c levels following
periodontal treatment concluded an average reduction of
0.46% of HbA1c in diabetic patients who received periodontal
treatment [40]. Thus, it is evident that there is a bidirectional
relationship between PD and diabetes; the mechanisms of
which are not fully understood but are thought to relate to
the increased in pro-inflammatory mediators, which are in-
volved in both diabetes and PD. [36]
These studies highlight the importance of ensuring that
diabetes is well controlled in patients with periodontal disease,
and that periodontal treatment can positively influence diabet-
ic control.
Diabetes is a cause of xerostomia, as such, persistent dry-
mouth should be investigated appropriately [41]. Further to
this, the resulting immunocompromisation from chronic
hyperglycaemia predisposes diabetics to fungal infections, de-
layed healing after surgery, and acute dental infection that may
develop quicker and take longer to resolve [42]. Thus, it is
imperative for diabetics to undergo regular dental assessment
and have an appropriate prevention strategy implemented.
Lupus
The ADs discussed thus far do not directly impact the oral
cavity, i.e., the auto-antigens are not directed against the oral
cavity. However, Systemic Lupus Erythematous (SLE) repre-
sents an interesting challenge due to its heterogeneous clinical
manifestations—one of which being oral mucosal lesions.
Lupus is described as a rare disease with an incidence of
4.91/100,000 people over a 3-year period; however, although
incidence appears to be declining, its prevalence appears to be
rising to 97.04/100,000 in 2012. Persons of Black Caribbean
ethnicity have the highest incidence and prevalence [43].
There is a higher female predilection in SLE, with an affected
female to male ratio of 10–15:1 [44].
Lupus is a chronic AD, which affects multiple body sys-
tems including the respiratory, dermatological, musculoskele-
tal, renal, and cardiovascular systems. Lupus goes through
periods of remission and relapse, increasing the complexity
of disease management. The varied presentation of lupus is
likely due to auto-antibodies being produced against nuclear
and cell membrane phospholipid components. The American
College of Rheumatology use the presence of auto-antibodies
for double-stranded DNA and antibodies against snRNP as
lupus diagnositics [45]. These molecules are associated with
apoptosis [46].
SLE auto-antibodies target the oral cavity directly, resulting
in erythema and/or erosion with surrounding white striae, sim-
ilar to that seen in oral lichen planus. Lupus lesions can affect
any oral site. However, compared with lichen planus, lupus
lesions more often present on the palate. Oral squamous cell
carcinoma may arise within these sites, suggesting that it may
be potentially malignant [47]. As with other ADs, treatment
for SLE often results in immune compromise leading to an
increased risk of fungal infection.
A recent study shows that SLE has negative effects on oral
health that extend to compromise the quality of life. The exact
mechanisms of this are unclear [48].
Oral Lichen Planus
Oral lichen planus (OLP) is a chronic inflammatory condition.
Both antigen-specific and non-specific mechanisms play a
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role in its pathophysiology [49]. OLP manifests as a result of
apoptosis of basal keratinocytes—induced by CD8+ T cells
(Fig. 2B). This damage to the basal layer makes it easier for
leukocytes to move into the intra-epithelial space and results
in self-perpetuating inflammation [50]. In addition, there are
more degranulated mast cells present in OLP tissue compared
to normal oral mucosa; degranulated mast cells release pro-
inflammatory mediators and upregulate endothelial cell adhe-
sion molecules, shown to be important in OLP pathogenesis
[49, 51, 52]. Clinically, this results in painful areas of erythe-
ma, erosions, and white patches. This primarily affects the
tongue and buccal mucosa but may also present as
desquamative gingivitis. OLP is potentially malignant, and
transformation occurs in around 1% of cases [53]. OLP prev-
alence is between 1 and 2% and has a female predilection [54,
55]. Lichen planus may also affect skin and genitals, these
sites are implicated in 20 and 15% of OLP cases, respectively.
OLP is seen in 70–77% of cutaneous lichen planus [56].
Whilst the exact cause of OLP remains elusive, genetic and
environmental factors play a role in its pathogenesis [57•].
Environmental factors involved in OLP include trauma, dental
materials, toothpastes, and systemic medications [56].
Oral Lichenoid Reactions (OLR) can be seen as either an
exacerbation of OLP to an environmental factor or a separate
disease entity, removal or modification of this factor will result
in improvement or resolution of the lesions [56].
There is no cure for OLP as such management is focused
on the symptomatic control of the disease. Treatment of the
disease includes the modification of exacerbating factors, such
as change of mediations implicated in OLP, removal and re-
placement of amalgam fillings, and modification of sharp den-
tal cusps [58]. Topical agents used include benzydamine or
steroid preparations [59]. In more severe cases, immune-
modulating drugs such as tacrolimus, retinoids, dapsone, and
mycophenolate may be necessary [51].
SLE has a similar clinical presentation to OLP, and graft
versus host disease, which affects 40–70% of engrafted pa-
tients that may present with similar clinical and histologic
features. Hence, differential diagnosis for suspected OLP le-
sions is important [60–62].
Pemphigus
The vesico-bullous disorder pemphigus is an AD with the
clinical presentation of blisters which evolve to painful ero-
sions that can affect both skin and mucous membranes [63].
Bullae formation occurs as a result of acantholysis caused by
the destruction of desmosomes. Specifically, IgG auto-
antibodies are directed against desmoglein 3 and desmoglein
1, resulting in loss of intra-epithelial keratinocyte adhesion
[63] (Fig. 2C).
Oral presentation of pemphigus occurs in 50–90% of cases
and is the first manifestation of the disease in around 18% of
patients. Blisters and ulcerations can be present in any area of
the oral mucosa, but most frequently those exposed to trauma
[64].
Diagnosis of the disease is reached through clinical, histo-
logic, and immunologic examination. Clinically, if pressure is
applied often blisters will result, known as Nikolsky’s sign,
this may indicate the presence of a blistering condition; how-
ever, concerns are raised as to its specificity and sensitivity, as
well as the adverse effect of inducing blisters [63]. The histo-
logic examination should be undertaken, specifically, direct
immunofluorescence will often identify a ‘basket weave’ ap-
pearance, showing the intra-epithelial location of auto-anti-
bodies. Indirect immunofluorescence will detect circulating
antibodies [63, 65].
Treatment of pemphigus is focused on providing symptom-
atic relief. Systemic corticosteroids, mycophenolate, and aza-
thioprine are commonly used in the management of pemphi-
gus. The biologic agent rituximab, a monoclonal anti-CD20
antibody, has been shown to achieve complete remission in
59–100% of cases; however, a relapse rate of 40–81% is re-
ported [63].
Pemphigoid
Pemphigoid has a similar presentation to pemphigus, namely
the formation of blisters, which often result in painful ulcers
when burst [66, 67]. It can affect the skin in addition to mu-
cous membranes. This results in a sub-epidermal blister, these
are more robust than those seen in pemphigus, and
Nickolsky’s sign is negative [64, 68].
The blisters result from IgG auto-antibodies directed against
collagen XVII and dystonin-e; this in turn leads to destruction of
hemidesmosomes responsible for the attachment of the epider-
mis and epithelium to basement membranes (Fig. 2D). The fac-
tors that induce pemphigoid are not understood. A genetic pre-
disposition is important in its aetiology [69].
Clinical, histopathological, and immunofluorescence are
employed in reaching a diagnosis of pemphigus. Histologic
findings may show subepithelial bulla with some inflamma-
tion [67, 70]. Direct immunofluorescence is the gold standard
for diagnosis of pemphigoid. It will typically show IgG at the
basement membrane in a linear appearance, allowing differ-
entiation between it and pemphigus [71], [72] (Fig. 2E).
Indirect immunofluorescence will show the presence of IgG
antibodies [72].
Management of pemphigoid typically involves the use of
systemic corticosteroids, and topical steroids may also be used
in addition to or in isolation, if the affected area is small.
Systemic treatment may include methotrexate and dapsone
[67].
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Conclusion
ADs can directly and indirectly affect the oral cavity and have
a variety of clinical presentations. Whilst we still do not fully
understand some of the mechanisms that cause ADs in the
mouth or the mechanisms that cause systemic AD to impact
the oral cavity, clearly, there is a bidirectional relationship.
Maintaining good oral health is an important, yet often
overlooked, component to the management of patients with
ADs. Further studies will elucidate insights to the exact mech-
anisms that regulate AD in the oral cavity and the relationship
between systemic AD and the oral cavity.
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